ABL Bio Inc (298380.KQ) stock: key figures, P/E, revenue and dividend

Energy · Coal & Consumable Fuels · South Korea · ISIN KR7298380007

Price
37,050.00 KRW
Market cap
2.04 tn KRW
P/E (2025)
–
P/S (2025)
25.74
Dividend yield
0.00 %
Net margin
-47.65 %
Return on equity (ROE)
-24.44 %
Return on assets (ROA)
-13.46 %

ABL Bio Inc financials

Fiscal year20242025
Revenue33.40 bn KRW79.35 bn KRW
Gross profit33.40 bn KRW79.35 bn KRW
Operating income-59.38 bn KRW-40.28 bn KRW
EBIT-55.49 bn KRW-36.88 bn KRW
Net income-55.53 bn KRW-37.81 bn KRW
Diluted EPS – continuing operations-1,150.11 KRW-685.83 KRW

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About ABL Bio Inc

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.